Big Gains Ahead in This Health-Care Winner

Nicholas Vardy

Nicholas Vardy has a unique background that has proven his knack for making money in different markets around the world.

It was another solid week for both U.S. and global stock markets. The S&P 500 was up 2.42% and the NASDAQ jumped 3.31%. Even the MCSI Emerging Markets Index recovered 4.15% — its strongest weekly gain in many months.

Big gainers in your Bull Market Alert portfolio included your leveraged bet on the price of gold — ProShares Ultra Gold (UGL), up 10.27%; the iShares Dow Jones US Home Construction (ITB), jumping 7.33%; Bank of Ireland (IRE), climbing 5.48%; and Delphi (DLPH), rising 4.79%.

Four out of your current Bull Market Alert positions — Delphi (DLPH), Jazz Pharmaceuticals (JAZZ), Stratasys Ltd. (SSYS) and iShares Dow Jones US Home Construction (ITB) are showing double-digit percentage gains.

Although Melco Crown (MPEL) rose 2.67% last week, with the Chinese stock market under substantial pressure, I am recommending that you sell your stock position to roughly break even. Also, sell your MPEL options, which expire this Friday at a loss.

This week’s Bull Market Alert recommendation — WellPoint, Inc. (WLP) — revisits the controversial, but profitable, health-care sector.

WellPoint, Inc. (WLP) is one of the nation’s largest health-benefits companies and is particularly well positioned to benefit from Obamacare.

Here’s why I think you’ll see double-digit percentage gains in this stock in the weeks ahead.

First, WellPoint already holds the number one market share position in the country in selling directly to the consumer. It also is tops among small-group employees purchasing coverage. Meanwhile, the company has invested about $150 million to prepare for the new health-insurance exchanges. You’re likely to see a lot of WellPoint signs in your local Walgreen’s over the coming years.

Second, in December of 2012, WellPoint acquired Amerigroup. The expanded WellPoint now serves more than 36 million medical members and has a Medicaid presence in 20 states — the largest in the industry. WellPoint’s size and scale provide it with significant bargaining power with health-care providers. For investors, that translates into higher margins and higher profits versus smaller competitors.

Exclusive  Daily Data Flow: Stocks Rise on Rumors; Election Intrigue

Third, WellPoint’s management is clearly committed to maximizing shareholder value. In 2012, WellPoint repurchased a staggering 39.7 million shares, or 11.7%, of its own shares outstanding. That improves both earnings per share and investment returns to investors.

Finally, from a fundamental perspective, WellPoint sells at a Price-to-Earnings (P/E) ratio of only 10, a more than 20% discount to the 12.2 median P/E of its peers. Meanwhile, WellPoint’s new senior management projects double-digit earnings per share (EPS) growth over the next five years.

From a shorter-term trading perspective, the health-care sector is among the strongest performers in Q3. Indeed, WLP has substantially outperformed the S&P 500 over the past three months.

So buy WellPoint, Inc. (WLP) at market today, and place your stop at $79.00.

If you want to play the options, I recommend the December $87.50 Calls (WLP131221C00087500).

Portfolio Update

Bank of Ireland (IRE) added 5.48% last week. Although the Irish recovery has stepped out of the media spotlight over recent weeks, the trend remains quietly positive. When Ireland suffered its banking crisis several years ago, the Irish government literally “chose a few winners” and IRE was the strongest of the lot. In fact, Bank of Ireland was so much stronger that it was able to secure a hefty amount of private funding to keep it afloat. IRE is scheduled to report earnings Aug. 2, before the market opens. IRE touched its 50-day moving average (MA) last Friday, but remains just shy of it, and is a HOLD.

Delphi Automotive (DLPH) added 4.79% last week, continuing with its third winning week in a row. DLPH is up an amazing 40% year-to-date and up 30% since your purchase. You booked a 62.06% gain on half of your DLPH options last week. DLPH will report earnings on July 31, before markets open. Hitting another 52-week high last week, DLPH remains a BUY.

Exclusive  Summer of 2013: Out with a Whimper

Stratasys Ltd. (SSYS) gained 1.54% last week. Expect some significant volatility in SSYS over the next week or so as it challenges the weighty $95.00 price level. Investors have been to this high twice before this year, making the third time likely a charm as the 3D-printing boom rolls on. SSYS is scheduled to report earnings on Aug. 1, before markets open. SSYS is a BUY.

Jazz Pharmaceuticals (JAZZ) gained 0.87% and hit a new all-time high of $74.43. Cantor Fitzgerald reiterated its “Buy” rating on JAZZ last week, setting a new $86.00 price target. This represents a possible 15.5% gain for the stock. Cantor Fitzgerald wrote that the Food and Drug Administration’s (FDA) decision to place more regulation on generic drug-makers is a positive development for JAZZ’s bottom line. JAZZ is a BUY.

Sony Corporation (SNE) rose 1.98%. Last week’s gain is the fourth weekly rise in a row for SNE. Sony is breaking new ground with its Xperia Z series of smartphones and tablets as it works its way into the formidable mobile computing market. A recent review by a technical guru found this new line of hardware to be a serious competitor to Apple’s iPad — still the current gold standard in the world of tablets. SNE will report earnings on Aug. 1, before markets open. SNE remains a BUY.

iShares Dow Jones US Home Construction (ITB) soared 7.33% last week, looking like it will finally break out from the sideways trading pattern at its 200-day MA. The 200-day MA is a prominent “Buy level” in most cases, and ITB seems to be moving upwards as the demand for new home construction begins to heat up. ITB is a BUY.

Exclusive  Bernanke's Gift To The Global Bull

ProShares Ultra Gold (UGL) was another big winner in your Bull Market Alert portfolio last week, powering 10.27% higher. With Federal Reserve Chairman Ben Bernanke back-pedaling a bit on his mere suggestion of winding down stimulus activities, gold investors can once again see the shine in gold. Gold posted some of its biggest gains since 2011 late last week and is extending those gains into early trading this morning. UGL is a BUY.

Latest Special Reports

As a courtesy, I want to bring to your attention my latest special report, Hedge Fund Secrets Revealed: A Simple Four-Step Technique to Manage Your Money like a Hedge Fund. This FREE report gives you the four-step process to maximize your profits just like the best investment pros do.

In addition, take a look at the latest version of The Top 12 Stocks You Should Buy Right Now, which features three of my top investment recommendations, as well as bonus picks from each of my fellow investment newsletter editors at Eagle. Both of these special reports are accessible FREE on my website.

PS: Join me for the San Francisco Money Show, Aug. 15-17, at the San Francisco Marriott Marquis. There is no charge for this conference, but you do need to register. Call 1-800/970-4355, and mention code #031736.

Like This Article?
Now Get Our FREE Special Report:
Alternative Investing: Investing in Timber

Stock Investor editor Paul Dykewicz reveals why investing in timber may be one of the best long-term portfolio strategies you'll find today.

Get Access to the Report, 100% FREE


img
previous article

LAS VEGAS--Astute stock pickers still have good investment opportunities, despite uncertainty about when the Fed will follow through with its stated plan to begin tapering its easy-money policies, several investment professionals said here at FreedomFest yesterday.

PREMIUM SERVICES FOR INVESTORS

Dr. Mark Skousen

Named one of the "Top 20 Living Economists," Dr. Skousen is a professional economist, investment expert, university professor, and author of more than 25 books.

Product Details

LEARN MORE HERE

Bryan Perry

A former Wall Street financial advisor with three decades' experience, Bryan Perry focuses his efforts on high-yield income investing and quick-hitting options plays.

Product Details

LEARN MORE HERE

Jim Woods

Jim Woods has over 20 years of experience in the markets from working as a stockbroker,
financial journalist, and money manager. As well as a book author and regular contributor to
numerous investment websites, Jim is the editor of:

Product Details

LEARN MORE HERE

Bob Carlson

Bob Carlson provides independent, objective research covering all the financial issues of retirement and retirement planning. In addition, Bob serves as Chairman of the Board of Trustees of the Fairfax County (VA) Employees’ Retirement System, which has over $2.8 billion in assets.

Product Details

LEARN MORE HERE

Mike Turner

Mike Turner’s financial, mathematical, computer science and engineering background serves as the foundation for his disciplined, rules-based approach to trading. Mike’s three services include:

Product Details

LEARN MORE HERE

Hilary Kramer

Hilary Kramer is an investment analyst and portfolio manager with 30 years of experience on Wall Street. Since 2010, Hilary's financial publications have provided stock analysis and investment advice to her subscribers:

Product Details

LEARN MORE HERE

DividendInvestor.com

Used by financial advisors and individual investors all over the world, DividendInvestor.com is the premier provider and one-stop shop for dividend information and research.

Product Details

Popular tools include our proprietary Dividend Calendar, Dividend Calculator, Dividend Score Card, and many more.

LEARN MORE HERE